Audited Financials Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported strong full-year results for FY2025-26 with consolidated revenue from operations growing 17.1% to ₹7,457.57 million from ₹6,369.10 million in the prior year. Net profit after tax jumped 29.6% to ₹1,736.08 million from ₹1,339.74 million, with EPS (basic) at ₹15.08 versus ₹11.72. The company generated positive operating cash flow of ₹1,567.76 million and total assets stood at ₹18,387.61 million. The Board recommended a final dividend of ₹1.35 per equity share (67.5% on face value of ₹2), while deferring any interim dividend to preserve capital for potential strategic actions. Auditors MSKA & Associates LLP issued an unmodified opinion with no going concern or emphasis of matter flags. Exceptional items include labour code implementation impact of ₹47.81 million (net charge) and a lawsuit provision reversal of ₹161.39 million (net credit). The company also reappointed its statutory auditors for a second five-year term and expanded its board with a new independent director.
The company delivered robust profit growth of ~30% YoY with healthy cash generation and a clean audit opinion, signalling strong operational performance. The deferred interim dividend and capital preservation strategy may be viewed as prudent by some investors while others may have expected more immediate shareholder returns.